Stifel Financial Corp Akebia Therapeutics, Inc. Transaction History

Stifel Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$3.16 - $6.73 $34,785 - $74,083	-11,008 Closed	0 $0
Q3 2019 Nov 19, 2019	BUY	$3.55 - $5.4 $39,078 - $59,443	11,008 New	11,008 $43,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $44,993 - $88,340	-10,974 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$5.41 - $8.73 $335 - $541	-62 Reduced 0.56%	10,974 $90,000
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $59,484 - $100,979	11,036 New	11,036 $61,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.